Almirall Q1 2025 Results
Almirall delivers a strong start to 2025: growing Q1 overall sales by 15%, and 23.4% in its European Dermatology business YoY, aligned with the company's sustained growth trajectory
Continued strong growth trajectory with 15% Net Sales increase to a total of €284.6 MM with key products delivering high double-digit YoY growth and general medicines business aided by Q1 2025 out-licensing transaction.
EBITDA increase of 35.0% YoY in line with expectations to a total of €70.9 MM driven by continued strong operational execution including out-licensing income realized in Q1 2025.
Performance was driven by the biologics portfolio, with Ilumetri® showing 12.7% increase in sales vs Q1 2024 (total of €55.1 MM), and Ebglyss® delivering €19.4 MM quarterly sales - mainly achieved by the continued positive launch dynamics in Germany and growing contributions from recent launched countries.
The broad dermatology product portfolio continues its sustained growth including performance in line with expectations of key products Wynzora® (22.2%, total of €7.7 MM) and Klisyri® (25.5%, total of €6.9 MM), further driving relevance of Almirall with patients and HCPs in Europe and other regions.
Guidance for the full year confirmed based on the strong performance in Q1 2025, and scrip dividend of €0.19 per share approved by the AGM on 9th May 2025.
BARCELONA, Spain, May 12, 2025--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global pharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2025. Almirall continued to deliver strong sales growth in the first quarter of the year - in line with expectations and with the longer-term growth trajectory set out by the company. Almirall's performance continues to be driven by its dermatology business in Europe, and by delivering advanced therapies and a broad portfolio of relevant and impactful products to more patients across markets.
Net Sales increased by 15% YoY to a total of €284.6 MM, EBITDA was €70.9 MM (increase of 35% YoY) driven by higher sales growth and recent out-licensing activities that also positively impacted that gross margin (66.9%). Dermatology sales in Europe increased by 23.4% to a total of €139.4 MM in Q1 2025.
The growth of Ebglyss® (lebrikizumab for the systemic treatment of moderate-to-severe atopic dermatitis) continues to further gain momentum delivering total Net Sales of €19.4 MM mainly based on the growth in its first launch market Germany and supported by growing contributions from recent launched countries. Including the launches in Q1 2025, Ebglyss is now available in 13 markets (Germany, Norway, UK, Spain, Denmark, Czechia, The Netherlands, Italy, Austria, Belgium, Sweden, Switzerland, and France in Q1) and the launch plans are on track with availability in all countries per plan expected to be achieved by end of 2025 (Portugal, Ireland, and Poland).
Ilumetri® (tildrakizumab for the systemic treatment of moderate-to-severe psoriasis) delivered double digit growth in Q1 2025 (12.7% increase YoY) and delivered solid Net Sales of €55.1 MM despite growing competition in the psoriasis market and some quarterly phasing impacts. Anti-IL-23 antibodies remain the leading class in advanced psoriasis treatments now and in the foreseeable future.
The biologics growth drivers were complemented by the strong performance of the broad portfolio of dermatology products leading to the dermatology portfolio overall growing 23.4% YoY in Q1 2025 in Europe to a total of €139.4 MM. Almirall's key products Wynzora® (psoriasis), and Klisyri® (actinic keratosis) grew double-digit in sales in Q1 2025 YoY.
Wynzora® continued to grow in its main markets and delivered total Net Sales of €7.7 MM representing a 22.2% increase vs Q1 2024. The strong double-digit growth performance of Klisyri® in Q1 2025 (€6.9 MM +25.5% YoY) is aligned with expectations of its increasing market share in key regions and was further supported by the US large field launch following the approval of the label extension by the FDA in 2024.
The overall performance in Q1 was supported by the strategic out-licensing and divestment of two products in the Spanish market in January 2025 (Sekisan and Algidol).
"We started the year with a continued strong business performance that is aligned with the long-term trajectory of sustained growth we have outlined for Almirall. Therefore, we are pleased to confirm our full year guidance for 2025 as we are delivering relevant and impactful treatments to more patients and physicians in medical dermatology. Our strong results across are driven by our advanced biologic treatments for patients with moderate to severe atopic dermatitis and psoriasis, and the consistent growth of our broader dermatology portfolio. Almirall is well positioned as European leader in medical dermatology, and we continue to invest to progress our early and late-stage pipeline, and to drive our commercial excellence to deliver sustained growth in the years to come."
Carlos Gallardo, Almirall Chairman and CEO
Financial highlights (€ rounded million)
Q1 2025
Q1 2024
Variation
Total Revenue
286.1
248.8
15.0%
Net Sales
284.6
247.4
15.0%
Other Income
1.5
1.4
7.1%
Gross Profit
190.4
157.2
21.1%
% of sales
66.9%
63.5%
EBITDA
70.9
52.5
35.0%
Net Income
21.6
7.4
191.9%
Normalized Net Income
22.1
7.5
194.7%
2025 Full Year Guidance
Full year guidance for 2025: double-digit net Sales growth of 10-13% and total EBITDA between €220 MM - €240 MM.
R&D pipeline
Almirall's continued investment in its leading R&D capabilities, and the medical dermatology pipeline are closely aligned with the company's long-term view on its contributions and commitment to positively impacting patients and society. Key milestones across the early and late-stage pipeline are expected to be delivered in 2025 including the progress of early-stage pipeline assets through clinical testing. Efinaconazole was authorized for launch in Italy on 20th March following its previous completion of the decentralized regulatory procedure in the EU. The interim phase I data for Anti-IL1RAP mAb were presented at the AAD 2025. A Phase II study to explore this antibody in patients suffering from Hidradenitis suppurativa is planned to start later this year.
Lifecycle management activities will further strengthen Almirall's key priority products with several ongoing clinical studies supporting our biologics in AD and PSO respectively as part of ongoing collaborative programs with its partners Lilly and Sun Pharma, respectively, to grow patient access & product value.
Partnership with the dermatology community
Almirall's close collaboration with dermatologists and life-science experts continue to be a key cornerstone for the company's dedication to medical dermatology. These partnerships expand Almirall's focus on fostering scientific exchange and to advance the understanding of skin diseases, treatment options, and their impact on patients.
In March, at the 2025 AAD congress, Almirall presented new data analysis from phase IV studies and real-world evidence with tirbanibulin for the treatment of actinic keratosis (AK) that showed consistently high levels of treatment response as well as patient satisfaction.
From 21st to 22nd March, Almirall hosted the 16th edition of its Skin Academy in Barcelona which is a unique opportunity for collaboration in medical dermatology as it – again - brought together leading experts from across the globe to advance science and innovative approaches for the treatment of skin diseases. The conference focused on the latest advancements in medical dermatology, including the holistic and personalized treatment of atopic dermatitis and psoriasis. It also covered a broad range of other skin diseases such as actinic keratosis, androgenetic alopecia, onychomycosis and chronic spontaneous urticaria - advancing the understanding of these diseases and treatment options to support better patient outcomes.
Dividend and Investor Calendar 2025
On 9th May, the Annual General Shareholder Meeting approved the distribution of a dividend charged to unrestricted reserves, for the amount of €0.19 per share. This will be applied using the scrip dividend shareholder remuneration system that has been applied in previous years.
H1 2025 Financial Results – 25th July 2025
9M 2025 Financial Results – 10th November 2025
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients' needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit almirall.com
Disclaimer
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250511285575/en/
Contacts
Corporate Communications corporate.communication@almirall.com Phone: +34 93 291 35 08
Investor Relations investors@almirall.com Phone: +34 93 291 30 87
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Vibes Nation
35 minutes ago
- Geek Vibes Nation
What Every Startup Can Learn From The Gaming Industry's Epic Business Model Evolution
By Matt Lhoumeau, CEO of Concord I'll never forget the first time I played World of Warcraft. It was 2005, I was working at a telecom company in France, and I couldn't understand why anyone would pay €13 every month just to play a game they'd already bought. Fast forward to today, and that 'crazy' subscription model generates billions annually. The gaming industry didn't just change how we play – it revolutionized how businesses think about customer relationships, revenue models, and long-term value creation. As someone who's built a company serving over 1,500 businesses, I've watched countless startups struggle with the same challenges game developers faced 20 years ago: How do you create sustainable revenue? How do you keep customers engaged? How do you scale without losing your soul? The answers, surprisingly, come from an industry that turned 'Game Over' into 'New Game+'. From One-and-Done to Games as a Service The gaming industry's transformation mirrors what every modern business needs to understand. In the 1990s, game developers had one shot: ship a cartridge, hope it sells, move on to the next project. Sound familiar? That's how most businesses still operate – one transaction, one customer interaction, hope for the best. Then everything changed. Games became services. Relationships became ongoing. Revenue became recurring. This shift didn't happen overnight, and it wasn't without casualties. For every Fortnite generating $5 billion annually from a free game, there's an Anthem or Babylon's Fall that crashed and burned. The difference? Understanding that the business model is as important as the product itself. The Free-to-Play Revolution: When Giving Away Your Product Makes You Rich Here's where it gets interesting for startups. The gaming industry discovered something counterintuitive: sometimes the best way to make money is to give your product away for free. League of Legends, one of the most profitable games ever created, costs nothing to play. Yet it generates over $1.5 billion annually. How? By fundamentally rethinking the value exchange. Instead of charging for access, they charge for enhancement. Instead of one big payment, they enable thousands of micro-transactions. Instead of hoping customers stay, they continuously provide reasons to engage. This isn't just about games. When we built Concord, we applied similar thinking. Instead of charging huge upfront fees like traditional enterprise software, we made it accessible to small businesses with flexible pricing. We learned that lowering barriers to entry while providing continuous value creates stronger, more profitable relationships than any one-time sale ever could. The Contract Behind the Controller What most people don't realize is that every modern game is essentially a complex web of contracts and agreements. When you download Fortnite, you're not just getting a game – you're entering into terms of service, privacy agreements, content licenses, and potentially hundreds of micro-contracts for every in-game purchase. This is where my world intersects with gaming in fascinating ways. Modern game companies need sophisticated procurement contract management software to handle relationships with: Platform providers (Steam, Epic, PlayStation, Xbox) Payment processors for multiple currencies and methods Cloud service providers for massive multiplayer infrastructure Content creators and licensing partners Localization and distribution partners globally One AAA game studio we work with manages over 3,000 vendor contracts just for a single game launch. Miss a renewal with your cloud provider? Your game goes offline. Mess up a licensing agreement? Your soundtrack disappears. The stakes are massive, and manual management is impossible. Data: The Real Power-Up Gaming companies were among the first to truly understand the power of analytics. Every click, every purchase, every rage quit – it's all data that drives decisions. Riot Games processes 500 billion events monthly from League of Legends alone. That's not just impressive; it's instructive. Modern contract analytics software applies the same principles to business operations. Just as game developers track player engagement to optimize experiences, businesses can track contract performance to optimize relationships. Which vendors deliver on time? Which contracts generate the most value? Where are the bottlenecks in your approval process? The gaming industry learned that data without action is just expensive storage. The same applies to any business. It's not enough to collect information – you need systems that surface insights and enable rapid response. The Subscription Economy: Lessons from the MMO Masters Remember when buying software meant getting a box with CDs? Gaming killed that model first. World of Warcraft proved that players would pay monthly for ongoing value. Xbox Game Pass took it further – why buy games when you can access hundreds for $15/month? This shift required fundamental changes in how companies operate: Continuous Content Creation : You can't charge monthly for a static product. Game developers learned to ship updates constantly, creating reasons for players to stay engaged. Every business needs to think the same way – what's your content strategy? Community Management : Subscription models live or die on retention. Gaming companies invest heavily in community managers, moderators, and engagement specialists. Your customer success team is your guild leader. Predictable Revenue Operations : When players subscribe, you can forecast revenue months in advance. But this requires sophisticated systems to manage billing, renewals, and churn prevention – exactly the kind of operational excellence that modern contract management enables. The Platform Play: Building Ecosystems, Not Just Products Perhaps the biggest lesson from gaming is the power of platforms. Steam didn't just sell games – it became the place where PC gaming happens. Epic Games leveraged Fortnite's success to launch a competing store. Roblox turned players into developers, creating a $45 billion ecosystem where users generate the content. For startups, this means thinking beyond your immediate product. How can you create a platform that others build upon? How can you turn customers into partners? How can you enable ecosystem growth? This requires sophisticated partner management, clear agreements, and scalable operations – challenges that multiplayer game developers have been solving for years. The Dark Side: Lessons from Loot Box Controversies Not every gaming innovation should be copied. The loot box controversy teaches valuable lessons about customer trust and sustainable practices. When EA's Star Wars Battlefront II locked progression behind randomized purchases, the backlash was swift and severe. The game that was supposed to print money became a cautionary tale. The lesson? Short-term monetization tactics that exploit customers will eventually backfire. Building sustainable businesses requires balancing value creation with value capture. Your pricing model should feel fair, transparent, and aligned with customer success. Your Next Level Awaits The gaming industry's evolution from product to service, from transaction to relationship, from single-player to massive multiplayer, offers a masterclass in business model innovation. But these lessons only matter if you can execute on them. Here's your quest log for applying gaming wisdom to your startup: Rethink Your Revenue Model : Are you still selling products when you could be providing services? Consider how subscription, freemium, or platform models might transform your business. Invest in Infrastructure : Just as modern games require robust backend systems, your business needs operational excellence. Automate what you can, starting with critical processes like contract management. Embrace Continuous Delivery : Ship early, ship often, respond to feedback. The days of 'fire and forget' are over. Your product should evolve constantly. Build Community, Not Just Customer Base : Your most engaged users are your greatest asset. Invest in tools and processes that enable community growth. Make Data-Driven Decisions : If game companies can analyze billions of events, you can track your key metrics. Start with the basics and scale from there. Prepare for Global Scale : Gaming went global because digital distribution made borders irrelevant. Is your business ready for international growth? The gaming industry transformed because it had to. Faced with technological change, shifting consumer expectations, and intense competition, developers either evolved or disappeared. Every industry faces similar pressures now. The question isn't whether you need to transform – it's whether you'll learn from those who've already blazed the trail. Game Over? Not even close. For smart startups willing to learn from gaming's epic evolution, it's just the beginning of a whole new adventure. Ready Player One? Matt Lhoumeau is the co-founder and CEO of Concord, a contract management platform trusted by over 1,500 companies. A lifelong gamer turned entrepreneur, Matt discovered parallels between gaming's digital transformation and the operational challenges facing modern businesses.
Bloomberg
3 hours ago
- Bloomberg
Ireland Needs Fiscal Rule as Economic Risk Grows, Watchdog Warns
The Irish government should commit to a domestic fiscal rule so it can better plan spending as the economy enters uncertain territory, the state's fiscal watchdog warned. A global trade war stoked by US President Donald Trump is likely to have an outsized impact on Ireland, the strategic tax base for several multinational firms. Sticking to a fiscal rule would set a sustainable growth rate for spending net of tax changes, the Irish Fiscal Advisory Council said in its June fiscal assessment report.
Yahoo
4 hours ago
- Yahoo
American Airlines Is Giving Onboard Service a Major Upgrade
American Airlines Is Giving Onboard Service a Major Upgrade originally appeared on Parade. Attention all traveling foodies: American Airlines is rolling out a deliciously major upgrade. The airline is celebrating some of its popular summer travel destinations with a new European-inspired in-flight dining menu beginning June 11 for customers flying in Flagship Business, a Flagship Suite Preferred seat, or a Flagship Suite seat on select European routes. Routes that will feature the menu include Paris (CDG) and Nice (NCE), France; Rome (FCO), Venice (VCE), Naples (NAP), and Milan (MXP), Italy; Barcelona (BCN) and Madrid (MAD), Spain; Frankfurt (FRA) and Munich (MUC), Germany; London (LHR) and Edinburgh (EDI), United Kingdom; and Dublin (DUB), Ireland. The menu items inspired by France are ratatouille and a porcini short rib paired with polenta and blue cheese, while the Italian-inspired menu features an herbed short rib with pea risotto and pan-seared halibut with fingerling potatoes. Would it be a German menu without schnitzel and spaetzle? American Airlines isn't taking that risk, adding both to the menu with potatoes and blistered tomatoes accompanying the schnitzel, and grilled zucchini, cremini mushrooms and sun-dried tomatoes joining the spaetzle. The theme continues with the Spain-inspired menu items, going coastal with a mar y mar paella and a seared sea bass served with squid ink rice, while the U.K. is represented with mustard-crumb lamb served with turnips, peas and baby carrots, and a peppercorn short rib with roasted potatoes and seasonal vegetables. That's not the only change being implemented, as the airline is now giving customers more time to make their pre-order selections by adjusting the pre-order meal window to 20 hours before departure, giving them four additional hours than they currently have to select their in-flight meal. Next: American Airlines Is Giving Onboard Service a Major Upgrade first appeared on Parade on Jun 9, 2025 This story was originally reported by Parade on Jun 9, 2025, where it first appeared.
